דלגו לתוכן

BMO קפיטל העלתה את מחיר היעד של ברייטספרינג הלת' ל-60 דולר מ-52 דולר

דה פליי (TheFly)4 במאי 2026
BMO קפיטל העלתה את מחיר היעד של ברייטספרינג הלת' ל-60 דולר מ-52 דולר

BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $52 and keeps an תשואת יתר rating on the shares. The magnitude of the company’s Q1 earnings beat was the largest yet while the management also raised its outlook for revenue and EBITDA in FY26, the analyst tells investors in a research note. The backdrop for Specialty Pharmacy remains encouraging, with BrightSpring still expecting to win 20 Limited Distribution Drugs in 2026 and benefit from multiple large generic conversions over the coming quarters, BMO added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>